Abstract: Synthetic adenoviruses having chimeric fiber proteins and liver detargeting mutations are described. The synthetic adenovirus vectors are capable of specifically infecting cells at wound sites or in regions of damaged tissue. The synthetic adenovirus vectors also are capable of expressing transgenes, such as wound healing factors, at sites of wounded or damaged tissue. Accordingly, the described vectors can be used to detect wounded or damaged tissue, and/or to promote wound healing and regeneration of damaged tissue, such as by expression of heterologous wound healing or tissue regeneration factors.

Abstract: The present invention relates to a composition for the prevention or treatment of arthritis, the composition containing a Sargassum serratifolium extract as an active ingredient. The extract of Sargassum serratifolium according to the present invention has an excellent activity to reduce or inhibit the activity of IL-1?, IL-6, or TNF-?, which is an inflammatory cytokine, and has an excellent effect alleviating arthritis in an arthritis animal model so that it can be usefully used as a composition for treating arthritis. In addition, there is no cytotoxicity, and toxicity to the drug and side effects are avoided so that it can be safely used even for long-term use, and it is stable in the body.

Abstract: Methods and compositions for treating wounds are described. The compositions include core active ingredients derived from the genera of: Calendula, Achillea Millefolium, Syzygium Aromaticum and Helichrysum. The methods include mixing the core active ingredients, preferably with other secondary active ingredients, adjuvants or excipients, to form the composition and administering the composition by topically applying an effective amount of the composition onto a wound or incision of a patient.

Abstract: A method of diminishing the appearance of or effecting the removal or disappearance of seborrheic keratoses by the application of compositions containing a) one or more, preferably a combination of, dietary antioxidants and/or antioxidant sources, b) one or more hydrating agents and c) one or more keratolytic agents.

Abstract: The present application is directed to transdermal formulations comprising one or more capsaicinoinds, one or more 1,4-dialdehyde sesquiterpenes, a penetration enhancer comprising tetrahydropiperine and a transdermal formulation base. The formulations advantageously show improved color characteristics and cause less irritation compared to other known transdermal or topica formulations comprising capsaicinoinds.

Abstract: The present invention relates to compositions and methods for the treatment of topical skin conditions, comprising of peppermint oil, lavender oil, tea tree oil and a suitable amount of a pharmaceutically acceptable carriers, shea butter and coconut oil.

Abstract: A composition comprising caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, said caffeoylshikimic acids and their derivatives extracted from any part of oil palm including but not confined to the vegetation liquor of palm oil milling and palm oil mill effluent, and a method for use in the preparation of a composition containing caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, said caffeoylshikimic acids and their derivatives.

Abstract: Various embodiments relate to formulations containing an extract of Alpinia galanga; a method of improving cognitive performance by administering an extract of Alpinia galanga; and a process for preparing an extract of Alpinia galanga.

Abstract: The compounds of the present invention are represented by the following compounds having Formula I, where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic), where the substituents R1-R4, RX, RY, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

Abstract: The proposed drug relates to medicine and veterinary applications, in particular, as a means for effective control of acute and/or chronic pain, and may be used in emergency medicine for the treatment of acute and/or chronic pain, including the late stages of cancer. The stated means is based on a compound for preventing and/or treating acute or chronic pain in a subject, including an analgesic peptide having an amino acid sequence H-Tyr-D-Arg-Phe-Gly-NH2 or an amino acid sequence H-Tyr-D-Arg-Phe-Sar-OH. Also, a method of use/administration of the compound for the prevention and/or treatment of acute and/or chronic pain is disclosed.

Abstract: The present invention provides, among other things, methods of treating a muscular dystrophy including administering to a subject suffering from or susceptible to a muscular dystrophy an angiotensin (1-7) peptide. The present invention is, in part, based on the unexpected discovery that administration of an angiotensin (1-7) peptide in a muscular dystrophy animal model reduces fibrosis, restores locomotor activity and restores sympathovagal balance, which are characteristic symptoms in patients suffering from muscular dystrophy. Thus, the present invention provides a new and more effective therapy for muscular dystrophy. In some embodiments, an angiotensin (1-7) peptide includes the naturally occurring angiotensin (1-7) amino acid sequence of Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7 (SEQID NO:1). In some embodiments, the angiotensin (1-7) peptide is a functional equivalent of SEQ ID NO:1. In some embodiments, the linear peptide has an amino acid sequence of Asp1-Arg2-Val3-Ser4-Ile5-H?is6-Cys7 (SEQ ID NO:2).

Abstract: The invention relates to a specific peptide combination. The peptide combination may be present in a pharmaceutically acceptable composition. The peptide combination can be used in the therapy or prevention of Type 1 Diabetes (TID). The invention also relates to a method of diagnosing or determining treatment efficacy, the method utilising the specific peptide combination.

Abstract: Methods, and compositions are provided for inhibition of histamine and non-histamine dependent itch signal transmission or scratch behavior. In one aspect, the present invention further comprises administering to the subject an inhibitor of histamine-dependent itch signal transmission. In some cases, the inhibitor of histamine independent itch signal transmission comprises an NK-1 receptor antagonist or the inhibitor of histamine independent itch signal transmission comprises a GRP receptor antagonist. In some cases, the method comprises administering two inhibitors of histamine independent itch signal transmission. For example, the inhibitors of histamine independent itch signal transmission can comprise an NK-1 receptor antagonist and a GRP receptor antagonist. In another embodiment, the invention provides a method of treating itch comprising administering to a subject suffering from itch an NK-1 receptor antagonist, a GRP receptor antagonist, and an AMPA receptor antagonist.

Abstract: The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.

Abstract: Provided are a pharmaceutical composition for preventing or treating Mycobacterium sp. infection or a related symptom thereof, wherein the pharmaceutical composition includes a compound including a peptide represented by Formula 1, or an isomer, a derivative, a solvate, or a pharmaceutically acceptable salt thereof; and a method using the same. The pharmaceutical composition has anti-Mycobacterium tuberculosis activity against Mycobacteria, e.g., Mycobacterium tuberculosis, and palliates inflammatory response caused by Mycobacterium tuberculosis. Thus, the pharmaceutical composition may be used in preventing or treating Mycobacterium sp. infection or a related symptom thereof.

Abstract: The present invention concerns a method for the prevention and/or treatment of an activation-induced deaminase (AID)-associated disease in a subject in need thereof, said method comprising administering an effective amount of an uracil-DNA glycosylase (UNG) inhibitor, or a composition comprising the inhibitor, and a pharmaceutically acceptable carrier, to a subject having pathogenic cells expressing AID, uracil-DNA glycosylase (UNG) and mismatch repair pathway (MMR). Also provided are kits comprising an UNG inhibitor, methods of stratifying a subject having an AID-associated disease, uses and compositions for use of the UNG inhibitor.

Abstract: Antimicrobial peptides, compositions and methods are described that are useful for treating infectious diseases, including those caused by drug resistant Gram-negative bacteria (e.g., Pseudomonas and Acinetobacter) and parasite-caused diseases such as malaria. The peptides include a modular kinocidin gamma-core connected directly, or through a short spacer, to a kinocidin C-terminal alpha-helix.

Abstract: The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of respiratory disorders.

Abstract: The invention relates to the fields of biochemistry, pharmacy and oncology. The invention particularly relates to the use of novel stem cell markers for the isolation of stem cells. The invention further relates to the obtained stem cells and their use in for example research or treatment, for example, for the preparation of a medicament for the treatment of damaged or diseased tissue. In one of the embodiments, the invention provides a method for obtaining (or isolating) stem cells comprising optionally preparing a cell suspension from a tissue or organ sample, contacting said cell suspension with an Lgr 6 or 5 binding compound, identify the cells bound to said binding compound, and optionally isolating the stem cells from said binding compound. The invention further relates to means suitable for cancer treatment and even more specific for the treatment of cancer by eradicating cancer stem cells.

Abstract: The invention features compositions and methods for inhibiting bone loss and arthritis.

Abstract: The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPAR?2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.

Abstract: Disclosed are applications of a mussel adhesive protein or preparations thereof in treatment and prevention of diseases related to melanin. Specifically disclosed are applications of a mussel adhesive protein or preparations thereof in treatment and prevention of pigmentations such as chloasma, freckles, melanosis, applications in skin cancers represented by melanoma, and applications in treatment of pigmentation possibly caused by skin diseases or drugs.

Abstract: Provided are methods of improving wound healing in a subject by administering a therapeutically effective amount of CD24. Also provided are pharmaceutical compositions which comprise CD24 being in a formulation with a surfactant and a pharmaceutically acceptable carrier.

Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS: 1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.

Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

Abstract: The present invention relates to a novel polypeptide having chemokine activity and, more specifically, to a polypeptide composed of the amino acid sequence represented by SEQ ID NO: 1 and a use thereof. The polypeptide of the present invention is composed of SEQ ID NO: 1 and exhibits chemokine activity through the binding with CCR3, and thus, the polypeptide has a high utilization effect for various purposes, such as immunoregulation, and diagnosis, treatment, and medicine development for CCR3-mediated diseases or disease symptoms.

Abstract: The present disclosure provides compositions including an amylin receptor agonist and a beta-2-adreno-receptor agonist (e.g., an anti-hyperglycemia agent), compositions including at least two different anti-catabolic agents, compositions including at least two different anti-adiposity agents, methods of treating a condition (e.g., muscle wasting, muscle wasting-related condition, excess adiposity, an excess adiposity-related condition, and the like), methods of increasing muscle mass, formation of thermogenic brown adipose tissue (BAT), and/or decreasing white adipose tissue (WAT) content, methods of treating muscle wasting, methods of treating excess adiposity, and the like.

Abstract: The present invention relates to a CRH formulation having improved stability/efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also relates to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.

Abstract: The present invention relates to a composition comprising particles, wherein said particles comprise Poly(lactide-co-glycolide) polymer, therapeutically effective amount of liraglutide or a pharmaceutically acceptable salt thereof and a hydrophilic particle size modulating agent, wherein, the composition is free of added divalent metal ions. The composition provides effective blood glucose control for about 7 days when administered as once a week formulation to a period of about 30 days after single administration of a monthly dose to a patient in need thereof.

Abstract: Embodiment of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: A scaffold for promoting cartilage formation is provided that includes a crosslinked electrospun fiber, wherein the crosslinked electrospun fiber consists essentially of crosslinked gelatin. The crosslinked electrospun fiber is generally crosslinked with a crosslinker, and the crosslinker may be diisosorbide bisepoxide. The crosslinked electrospun fiber may be crosslinked by adding a crosslinker to a solution of gelatin at a desired concentration. The electrospun fiber may advantageously remain intact for 18 days or longer upon being immersed in an aqueous solution. A composition for promoting cartilage formation is also provided that includes the disclosed scaffold and a mesenchymal stem cell (MSC). The disclosed scaffold may include a crosslinked electrospun fiber that includes gelatin and sodium cellulose sulfate (NaCS), e.g., in an amount of up to 5% by weight of the amount of gelatin.

Abstract: The incidence of high blood pressure is strikingly high with advancing age, and is an independent prognostic factor for the onset or progression of a variety of cardiovascular disorders (CVD). There is a critical need for a curative therapy against age-related hypertension. Overexpression of human thioredoxin (Trx) a redox protein in mice prevented age-related hypertension. Chronic injection of recombinant human Trx (rhTrx) for 3-consecutive days reversed hypertension in aged wildtype mice that lasted for at least 20 days. Arteries of wildtype mice so injected or mice with Trx overexpression exhibited decreased arterial stiffness, greater endothelium-dependent relaxations, increased nitric oxide (NO) production and decreased superoxide anion (O2.?) generation compared to appropriate controls. Collectively, a translational role of rhTrx in reversing age-related hypertension with long lasting efficacy is disclosed.

Abstract: Disclosed herein are methods and compositions useful in the treatment and/or prevention of a disease or indication associated with accumulation of a bisretinoid, for example A2E. In many embodiments, the disclosed methods and compositions are useful in treating an eye disease, for example macular degeneration.

Abstract: The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).

Abstract: The present disclosure relates to the identification and the use of activators of a mammalian glycerol-3-phosphate phosphatase (hG3PP) for increasing Gro3P conversion to glycerol and glycerol release from a mammalian cell. The activators of hG3PP can be used in the prevention, treatment and/or alleviation of symptoms associated with obesity, type 2 diabetes and/or metabolic syndrome X. The activators of hG3PP can be used in the prevention, treatment and/or alleviation of symptoms associated with cancer.

Abstract: A method of treating a subject having or at risk for having an HIV-1 virus infection, by administering to the subject a therapeutically effective amount of a composition comprising a CRISPR-associated endonuclease, and two or more different multiplex guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-1 proviral genome, eradicating the HIV-1 proviral DNA from the host cell, and completely resolving the symptoms of HIV-1, decreasing the severity of the symptoms of HIV-1, or slowing HIV-1's progression.

Abstract: The present disclosure relates to compositions and methods for treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mucopolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a recombinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the enzymatic activity of the human GNS protein. The composition can be provided in an artificial cerebrospinal fluid. About 1 mg to about 100 mg of the recombinant polypeptide may be administered to the patient once every 2 weeks to 6 months.

Abstract: A method is disclosed for blocking or reducing a physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.

Abstract: This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

Abstract: The present invention relates to the use of elafin for the treatment and/or prevention of diseases or disorders associated with an increase in troponin levels, which are non elastase dependent. The present invention in a preferred embodiment relates to a method and composition, using elafin, for protecting the heart muscle or other muscles from damage induced by abnormal blood flow and/or inflammation, which may result from, for example, a heart infarction. The present invention additionally or concomitantly relates to the use of elafin for the treatment and/or prevention of disorders or diseases which are associated with a rise in the level of troponin I and/or T.

Abstract: The present invention provides for modified natural killer (NK) cells that are resistant to TGF-? stimulation due to suppressed Smad3 activity in these cells. Also provided are compositions comprising these modified NK cells, as well as methods of treating cancer by using the cells.

Abstract: An immunogenic composition is provided herein. The immunogenic compositions are used to identify and select immunogenic antigens that elicit immune responses in a subject and may be subsequently used in multi-antigen vaccine compositions against one or more diseases or conditions. According to some embodiments, the immunogenic composition may include a plurality of nucleic acid fragments or minigenes derived from a nucleic acid library, wherein each nucleic acid fragment encodes a different antigen or functional portion thereof, and wherein the different antigens or functional portions thereof are associated with one or more disease or condition. The immunogenic composition may also include a delivery medium loaded with the plurality of nucleic acid fragments and in some embodiments, the delivery medium is loaded with nucleic acid fragments in such a way that individual antigen presenting cells receive only a subset of the nucleic acids within a vaccine in order to minimize antigenic competition.

Abstract: Described herein are multilayer films that include modified polypeptide epitopes from Plasmodium falciparum, specifically a modified T* epitope. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes the modified T* polypeptide epitope from a Plasmodium protozoan.

Abstract: Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin antigen may contain at least two alterations that reduce its toxicity and/or may be conjugated to or co-administered with another bacterial antigen. The vaccines may comprise one or more other bacterial antigens. Antibody compositions comprising antibodies to alpha-toxin and optionally one or more other bacterial antigens also are provided, and are useful for treating and preventing infections.

Abstract: The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.

Abstract: The present invention provides immunogens which can be used for vaccines against non-typeable Haemophilus influenzae (NTHi). The protein targeted is NTHi PDE1 and is highly conserved making it a vital component necessary for bacterial pathogenesis. The protein preferably includes the C terminal fragment after cleavage between Asn269 and Gly270, when compared to the wild-type PDE1 amino acid sequence. Nucleic acid sequences, amino acid sequences, immunogenic compositions, treatments and methods of diagnosis are disclosed.

Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or compositions for such treatment.

Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

Abstract: This document provides methods and materials related to using monovalent anti-CD3 antibodies (e.g., monovalent anti-CD3 Fab fragments) as adjuvants to increase the immune response produced against an antigen (e.g., a tumor associated antigen). For example, vaccine compositions containing monovalent anti-CD3?? Fab fragments in combination with tumor associated antigens (e.g., tumor associated antigens having little or no immunogenicity in the absence of monovalent anti-CD3?? Fab fragments) alone or in combination with adjuvants for signals two and/or three required for full activation of T cell immune function, as well as methods and materials for using monovalent anti-CD3?? Fab fragments to increase the immune response produced against an antigen (e.g., a tumor associated antigen) within a mammal (e.g., a human) are provided.

Abstract: The present invention describes compositions, including pharmaceutical compositions, comprising a PD-1 axis binding antagonist, a CTLA4 antagonist, or a DNA demethylating agent and a benzamide compound and methods for use thereof, for example in the treatment of cancer. In some implementations, the methods for use including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.